15 Oct 2025
PCR @ TCT 2025 - Get the international perspective!
Everything you need to know about #TCT2025 - condensed take-home messages covering major late-breaking clinical trials, registries and studies
Thanks to the contribution of a team of interventional cardiologists from around the globe, get the international perspective on Late-breaking Clinical Trials and Science released at TCT 2025 - check out the list below.
TCT 2025 - 25-28 October, 2025
Nicola Ryan, Mirvat Alasnag, Elad Asher, Luigi Biasco, Aaysha Cader, Ali Nazmi Calik, Jonathan Curio, Daniele Giacoppo, Kalaivani Mahadevan, Yohei Ohno and Alex Sticchi will review a selection of major Late-breaking Clinical Trials and Science (LBTs) in Interventional Cardiology released at the 2025 Transcatheter Cardiovascular Therapeutics Congress (TCT 2025). Don't miss out!
Late-breaking Clinical Trials and Science covered:
- One-year results of the SELUTION DeNovo trial comparing a strategy of PCI with a sirolimus-eluting balloon and provisional stenting versus systematic DES implantation to treat DeNovo coronary lesions
- Randomized comparison of intravascular lithotripsy vs. cutting balloon treatment in calcified coronary artery disease – The Short-CUT trial
- A randomized, multicenter, non-inferiority comparison of intravascular lithotripsy and super-high-pressure non-compliant balloons for treatment of calcified and refractory coronary lesions - The VICTORY trial
- Long-term follow-up of the PARTNER 3 Low-Risk randomized trial: Seven-year clinical and echocardiographic outcomes
- Tendyne transcatheter mitral valve system in patients with severe mitral annular calcification: One-year outcomes from the SUMMIT Severe MAC cohort
- Percutaneous transseptal transcatheter mitral valve replacement using a dedicated balloon expandable valve: 1 year outcomes from the ENCIRCLE trial using the SAPIEN M3
- Comparison of drug-coated versus conventional balloons for treatment of side branches of bifurcation lesions: The OCVC-BIF study
- Sirolimus-eluting iron bioresorbable scaffold in coronary artery disease: Two-year results of IRONMAN-II randomized controlled trial
- Effects of intracoronary low-dose recombinant tissue plasminogen activator as an ajunct to primary PCI in patients with STEMI and large thrombus burden: A randomized, double-blind, placebo-controlled trial (STRIVE)
- OCT insights of thrombus extraction by stent-retriever thrombectomy (SRT) and manual aspiration (MA): Insights from RETRIEVE AMI trial
- iFR versus angiography-guided CABG: 3-year results of the iCABG randomized trial
- Stratified treatment of myocardial infarction with non-obstructive coronary arteries: The PROMISE trial
- Randomized controlled trial of mechanical thrombectomy with anticoagulation versus anticoagulation alone for acute intermediate-high risk pulmonary embolism: Results from STORM-PE
- The effectiveness and safety of a planned investment procedure in high-risk chronic total occlusions - The INVEST CTO single arm study
- Percutaneous Coronary Intervention of Native Coronary Artery versus Saphenous Vein Graft in Patients with Prior Coronary Artery Bypass Graft Surgery (PROCTOR)
This independent ESC Congress 2025 coverage is available thanks to the unrestricted support of Cordis